Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

Accueil
Investir
Actions
Etats-Unis
NASDAQ
Synaptogenix Inc (SNPX)
Synaptogenix Inc (SNPX) Actualités

SNPX

Synaptogenix (SNPX)

Synaptogenix Inc

De:

Actualités Réglementées

Mots clefs:

Trier par:

Actualités Non-réglementées

Showing the most relevant articles for your search:NASDAQ:SNPX

1 2 3 Suivant >>

Date	Heure	Source	Titre	Symbole	Société
12/11/2024	23h00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SNPX	Synaptogenix Inc
07/11/2024	14h54	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:SNPX	Synaptogenix Inc
05/11/2024	12h01	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:SNPX	Synaptogenix Inc
28/10/2024	21h00	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:SNPX	Synaptogenix Inc
22/10/2024	06h15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:SNPX	Synaptogenix Inc
10/10/2024	23h11	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:SNPX	Synaptogenix Inc
04/10/2024	22h30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SNPX	Synaptogenix Inc
23/09/2024	23h04	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:SNPX	Synaptogenix Inc
11/09/2024	15h00	PR Newswire (US)	Synaptogenix Announces $5.0 Million Financing	NASDAQ:SNPX	Synaptogenix Inc
18/07/2024	15h00	PR Newswire (US)	Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury	NASDAQ:SNPX	Synaptogenix Inc
26/06/2024	15h00	PR Newswire (US)	Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis	NASDAQ:SNPX	Synaptogenix Inc
07/05/2024	15h00	PR Newswire (US)	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery	NASDAQ:SNPX	Synaptogenix Inc
24/04/2024	15h15	PR Newswire (US)	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	NASDAQ:SNPX	Synaptogenix Inc
09/04/2024	15h15	PR Newswire (US)	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics	NASDAQ:SNPX	Synaptogenix Inc
03/04/2024	14h00	PR Newswire (US)	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing	NASDAQ:SNPX	Synaptogenix Inc
06/02/2024	16h16	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:SNPX	Synaptogenix Inc
19/12/2023	15h00	PR Newswire (US)	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders	NASDAQ:SNPX	Synaptogenix Inc
06/12/2023	15h00	PR Newswire (US)	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's	NASDAQ:SNPX	Synaptogenix Inc
02/11/2023	14h00	PR Newswire (US)	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology	NASDAQ:SNPX	Synaptogenix Inc
26/09/2023	15h00	PR Newswire (US)	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease	NASDAQ:SNPX	Synaptogenix Inc
07/09/2023	15h00	PR Newswire (US)	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study	NASDAQ:SNPX	Synaptogenix Inc
19/07/2023	15h00	PR Newswire (US)	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis	NASDAQ:SNPX	Synaptogenix Inc
13/07/2023	15h00	PR Newswire (US)	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience	NASDAQ:SNPX	Synaptogenix Inc
22/06/2023	23h15	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:SNPX	Synaptogenix Inc
15/05/2023	22h51	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:SNPX	Synaptogenix Inc
31/03/2023	22h23	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SNPX	Synaptogenix Inc
21/03/2023	22h24	Edgar (US Regulatory)	Annual Report (10-k)	NASDAQ:SNPX	Synaptogenix Inc
07/03/2023	15h00	PR Newswire (US)	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities	NASDAQ:SNPX	Synaptogenix Inc
18/01/2023	22h29	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	NASDAQ:SNPX	Synaptogenix Inc
28/12/2022	22h16	Edgar (US Regulatory)	Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)	NASDAQ:SNPX	Synaptogenix Inc

Showing the most relevant articles for your search:NASDAQ:SNPX

1 2 3 Suivant >>

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales